Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on ATYR stock, giving a Hold rating yesterday.

Joseph Pantginis has given his Hold rating due to a combination of factors, including the mixed outcome of the prior Phase 3 EFZO-FIT trial, where the primary endpoint was not met largely because of an unusually strong placebo steroid reduction effect. While this setback tempers near-term enthusiasm, the drug still showed durable signals of clinical benefit in pulmonary sarcoidosis, supporting continued development rather than a more negative stance.

At the same time, the recent FDA Type C feedback provides a clearer, more favorable regulatory roadmap, with a redesigned Phase 3 focusing on restrictive lung disease patients, a more robust FVC primary endpoint, and stricter steroid-use controls that should reduce confounding. These improvements, along with an intensified dosing schedule, enhance the probability of success but also introduce execution risk and a longer development timeline, leading Pantginis to adopt a neutral Hold view instead of moving to a Buy or Sell recommendation.

In another report released yesterday, Wells Fargo also maintained a Hold rating on the stock with a $1.00 price target.